Truvestments Capital’s Kyntra Bio KYNB Stock Holding History

Truvestments Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2	Closed	-$1K	–	628
2021 Q2	$1K	Hold	2	–	–	﹤0.01%	589
2021 Q1	$1K	Buy	+2	New	+$2.13K	﹤0.01%	649

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truvestments Capital's KYNB Position: Q3 2021 in Review

Truvestments Capital sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 2 shares — an estimated $1K sold.

Truvestments Capital first reported a position in KYNB in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Truvestments Capital reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
Truvestments Capital sold 2 Kyntra Bio shares in Q3 2021, an estimated $1K.
Truvestments Capital first reported a position in Kyntra Bio in Q1 2021 and held it in 2 quarters.
Truvestments Capital's Kyntra Bio position peaked at $1K in Q2 2021.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Truvestments Capital's 13F filing for Q3 2021, filed 29 Oct 2021.